Healthcare Services

Lung Cancer Diagnostic And Screening Market Size Forecast To Achieve $4.03 Billion By 2030 With 9.6% CAGR

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Lung Cancer Diagnostic And Screening Market Between 2026 And 2030?

The market size for lung cancer diagnostics and screening has experienced robust expansion over recent years. Projections indicate it will expand from $2.56 billion in 2025 to reach $2.8 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. This historical growth can be ascribed to several factors, including the significant prevalence of smoking-related lung cancer, the extensive adoption of chest x-ray and ct imaging, the expansion of hospital-based diagnostic infrastructure, a heightened awareness regarding early lung cancer detection, and the rise of biopsy-based diagnostic confirmation.

The market for lung cancer diagnostics and screening is anticipated to experience substantial expansion over the coming years. This market is projected to reach $4.04 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.6%. Several factors are expected to drive this growth during the forecast period, including the broadening of national lung cancer screening programs, the wider uptake of low-dose CT screening, an increasing need for biomarker and blood-based tests, greater healthcare spending on oncology diagnostics, and enhanced availability of diagnostic imaging facilities. Key trends anticipated within this period involve the increasing embrace of early lung cancer screening initiatives, the expanded application of advanced imaging and biomarker testing, a heightened emphasis on screening high-risk demographics, the proliferation of non-invasive diagnostic methodologies, and the growing incorporation of multimodal diagnostic approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12043&type=smp

Which Drivers Are Advancing The Lung Cancer Diagnostic And Screening Market Growth?

The market for lung cancer diagnosis and screening is anticipated to expand due to the rising occurrence of lung cancer. This malignant condition, characterized by the uncontrolled spread of atypical cells in lung tissues, manifests with symptoms like coughing, chest pain, and breathing difficulties. Diagnostic and screening procedures for lung cancer enable early detection of the illness in patients through diverse tests, such as incisional biopsy and bronchoscopy. An illustrative example from January 2023, based on data from the American Cancer Society, a US-based government organization, indicated that the United States saw approximately 238,340 new cases of lung cancer (comprising 117,550 in men and 120,790 in women). Additionally, 127,070 lung cancer deaths were reported (with 67,160 affecting men and 59,910 affecting women). Consequently, the increased prevalence of lung cancer is a key factor propelling the expansion of the lung cancer diagnostic and screening market.

How Is The Lung Cancer Diagnostic And Screening Market Distributed Across Key Segments?

The lung cancer diagnostic and screening market covered in this report is segmented –

1) By Product: Instruments, Consumables And Accessories

2) By Test: Biomarkers Tests, Imaging Test, Biopsy, Blood Test, Other Tests

3) By Cancer Type: Non-Small Cell Lung Cancer, Small Cell Lung Cancer

4) By End User: Hospital, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Users

Subsegments:

1) By Instruments: Imaging Devices, Biopsy Devices, Bronchoscopy Systems

2) By Consumables And Accessories: Biopsy Needles, Reagents And Assays, Imaging Contrast Agents, Sample Collection Kits

Which Trends Are Supporting The Evolution Of The Lung Cancer Diagnostic And Screening Market?

Major companies in the lung cancer diagnostic and screening market are concentrating on developing blood-based tests that utilize machine learning, such as whole-genome machine learning, to provide accessible and convenient lung cancer screening and gain a competitive edge. Whole-genome machine learning refers to the application of machine learning algorithms for analyzing and interpreting comprehensive genetic information, encompassing an organism’s entire genome. For instance, in October 2023, DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, launched FirstLook Lung, a blood test employing whole-genome machine learning to analyze cell-free DNA fragments, thereby improving lung cancer screening with a 99.7% NPV. This test, designed for routine blood work, identifies individuals with potential lung cancer, including early-stage disease. Addressing low LDCT screening uptake, the test aims to improve population health.

Which Key Players Are Active In The Lung Cancer Diagnostic And Screening Market?

Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

Access The Complete Lung Cancer Diagnostic And Screening Market Report:

https://www.thebusinessresearchcompany.com/report/lung-cancer-diagnostic-and-screening-global-market-report

Which Region Commands The Largest Share Of The Lung Cancer Diagnostic And Screening Market?

North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Lung Cancer Diagnostic And Screening Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12043&type=smp

Browse Through More Reports Similar to the Global Lung Cancer Diagnostic And Screening Market 2026, By The Business Research Company

Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Respiratory Disease Testing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Lung Cancer Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795